ZIOPHARM Oncology, Inc. (WEK.F)

1.4100 0.0000 (0.00%) At close: 08:10AM CEST

ZIOPHARM Oncology, Inc.

2617 Bissonnet Street
Suite 225
Houston, TX 77005
United States
346 355 4099
https://www.alaunos.com

Sector(s): 
Industry: 
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Dale Curtis Hogue Jr.	Interim CEO & Director	N/A	N/A	1970
Ms. Melinda Lackey	Senior VP of Legal, Administration & Secretary	578.06k	N/A	1977
Mr. Michael Wong	Vice President of Finance & Principal Accounting Officer	N/A	N/A	1980

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Corporate governance

ZIOPHARM Oncology, Inc.’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 3; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.